Chris Raymond
Stock Analyst at Raymond James
(3.05)
# 1,358
Out of 5,090 analysts
9
Total ratings
77.78%
Success rate
50.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Downgrades: Outperform | $142 → $123 | $80.38 | +53.02% | 3 | Nov 14, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $40.29 | +11.69% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $21.50 | +62.79% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $109.60 | -4.20% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $5.89 | +290.82% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $38.77 | -22.62% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $9.55 | +685.34% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Nov 14, 2025
Downgrades: Outperform
Price Target: $142 → $123
Current: $80.38
Upside: +53.02%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $40.29
Upside: +11.69%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $21.50
Upside: +62.79%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $109.60
Upside: -4.20%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $5.89
Upside: +290.82%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $38.77
Upside: -22.62%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $9.55
Upside: +685.34%